Table 4.
Excess drug prescriptions for the periods with elevated activity compared to the peri-season, shown as numbers of prescriptions per 10,000 person-years (as % of peri-seasonal levels).
| Seasons | 0–1 years | 2–4 years | 5–19 years | 20–49 years | 50–54 years | 55–59 years | 60–64 years | 65+ years |
|---|---|---|---|---|---|---|---|---|
| Antibiotics | ||||||||
| RSV total | 3791 (65%) | 2326 (59%) | 248 (15%) | 236 (10%) | 264 (8.9%) | 431 (13%) | 572 (15%) | 669 (13%) |
| Influenza total | 1397 (24%) | 1328 (34%) | 417 (25%) | 407 (18%) | 461 (15%) | 615 (18%) | 796 (21%) | 761 (14%) |
| Influenza high risk | – | – | 819 (20%) | 761 (13%) | 717 (12%) | 827 (13%) | 1059 (16%) | 846 (12%) |
| Influenza low risk | – | – | 404 (25%) | 393 (18%) | 432 (17%) | 586 (22%) | 721 (24%) | 722 (19%) |
| Otologicals | ||||||||
| RSV total | 79 (14%) | 90 (17%) | a | a | a | a | a | a |
| Influenza total | 126 (22%) | 142 (27%) | a | a | a | a | a | a |
| Cardiovascular medication | ||||||||
| RSV total | – | – | a | a | a | a | a | a |
| Influenza total | – | – | a | b | 110 (8.7%) | 122 (7.4%) | 159 (7.4%) | 196 (6.3%) |
| Influenza high risk | – | – | a | a | a | a | a | 130 (3.3%) |
| Influenza low risk | – | – | a | b | 110 (11%) | 170 (13%) | 163 (10%) | 269 (11%) |
The number of persons was insufficient for valid estimation.
a
Result not statistically significant.
b
Although borderline significant not shown here for the whole age-group as further 5-year age-group specific analyses revealed that significance was related only to a significant and clinically relevant surplus for the age category 45–49: 113.12 (12.95%) and 122.78 (17.06%) for the total population and low-risk group, respectively.